Method for enhancing endothelial function in humans

• US 20030049250A1
• Filed: 09/05/2001
• Published: 03/13/2003
• Est. Priority Date: 09/05/2001
• Status: Abandoned Application

• Current Assignee: Hormos Medical Corp (Shionogi & Co., Ltd.)
• Original Assignee: Hormos Medical Corp (Shionogi & Co., Ltd.)
• Inventors: Raitakari, Olli, Jarvisalo, Mikko, Ronnemaa, Tapani, Jartti, Laura, Karvonen, Matti, Pesonen, Ullamari, Koulu, Markku
• Application Number:
  US09/946,174
• Publication Number:
  US 20030049250A1
• Time in Patent Office: Days
• US Class Current: 424/143.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 38/2271 Neuropeptide Y

Abstract

The present invention concerns a method for enhancing the endothelial function in humans, comprising administering to the person an NPY receptor active agent, wherein said receptor is present in the endothelial tissue. Furthermore, the invention concerns methods for the treatment or prevention of atherosclerotic vascular diseases; vascular spasm associated with angina pectoris; micro- or macrovascular complications of diabetes; premature ejaculation and impotence; or any disease or disorder where a deficit in the formation of nitric oxide for the vascular endothelium appears evident, said methods comprising administering to the person an NPY receptor active agent, wherein said receptor is present in the endothelial tissue.

Claims

1. A method for enhancing the endothelial function in humans, comprising administering to the person an NPY receptor active agent, wherein said receptor is present in the endothelial tissue.

2. The method according to claim 1 wherein said agent is an NPY receptor agonist.

3. The method according to claim 2 wherein said receptor is the Y2 receptor.

4. The method according to claim 3 wherein i) said agent also is a Y1-receptor agonist or antagonist, or ii) wherein a separate Y1 receptor agonist or antagonist is administered in combination with the Y2 receptor agonist.

5. A method for the treatment or prevention of atherosclerotic vascular diseases, comprising administering to the person an NPY receptor active agent, wherein said receptor is present in the endothelial tissue.

6. The method according to claim 5 wherein said agent is an NPY receptor agonist.

7. The method according to claim 6 wherein said receptor is the Y2 receptor.

8. The method according to claim 7 wherein i) said agent also is a Y1-receptor agonist or antagonist, or ii) wherein a separate Y1 receptor agonist or antagonist is administered in combination with the Y2 receptor agonist.

9. A method for the treatment or prevention of vascular spasm associated with angina pectoris, comprising administering to the person an NPY receptor active agent, wherein said receptor is present in the endothelial tissue.

10. The method according to claim 9 wherein said agent is an NPY receptor agonist.

11. The method according to claim 10 wherein said receptor is the Y2 receptor.

12. The method according to claim 11 wherein i) said agent also is a Y1-receptor agonist or antagonist, or ii) wherein a separate Y1 receptor agonist or antagonist is administered in combination with the Y2 receptor agonist.

13. A method for the treatment or prevention of micro- or macrovascular complications of diabetes, comprising administering to the person an NPY receptor active agent, wherein said receptor is present in the endothelial tissue.

14. The method according to claim 13 wherein said agent is an NPY receptor agonist.

15. The method according to claim 14 wherein said receptor is the Y2 receptor.

16. The method according to claim 15 wherein i) said agent also is a Y1-receptor agonist or antagonist, or ii) wherein a separate Y1 receptor agonist or antagonist is administered in combination with the Y2 receptor agonist.

17. A method for the treatment or prevention of any disease or disorder where a deficit in the formation of nitric oxide for the vascular endothelium appears evident, said method comprising administering to the person an NPY receptor active agent, wherein said receptor is present in the endothelial tissue.

18. The method according to claim 17 wherein said agent is an NPY receptor agonist.

19. The method according to claim 18 wherein said receptor is the Y2 receptor.

20. The method according to claim 19 wherein i) said agent also is a Y1-receptor agonist or antagonist, or ii) wherein a separate Y1 receptor agonist or antagonist is administered in combination with the Y2 receptor agonist.

21. A method for the treatment or prevention of premature ejaculation and impotence, said method comprising administering to the person an NPY receptor active agent, wherein said receptor is present in the endothelial tissue.

22. The method according to claim 21 wherein said agent is an NPY receptor agonist.

23. The method according to claim 22 wherein said receptor is the Y2 receptor.

24. The method according to claim 23 wherein i) said agent also is a Y1-receptor agonist or antagonist, or ii) wherein a separate Y1 receptor agonist or antagonist is administered in combination with the Y2 receptor agonist.